Beijing Tongwei Times Biotechnology

Beijing Tongwei Times Biotechnology is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative cell therapies for hematological malignancies and solid tumors. The company focuses on chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR-T) technologies to address unmet medical needs in oncology. Their lead programs include dual-targeting CAR-T therapies designed to overcome antigen escape and improve patient outcomes in B-cell malignancies. Tongwei Times leverages its proprietary cell engineering platform to enhance the persistence and efficacy of engineered T-cells. The company is actively advancing its pipeline through clinical trials in collaboration with leading medical institutions in China. Its manufacturing facility is designed to meet GMP standards for cell therapy production.